NCT03353454View on ClinicalTrials.gov

A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 25, 2018

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
DRUG

Maralixibat

Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.

DRUG

Placebo

Placebo matching to maralixibat orally twice daily for 26 weeks.

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY